Short answer
PHIBRO ANIMAL HEALTH CORP (PAHC) filed an 8-K current report with the SEC on April 27, 2026 reporting Item 7.01 (Regulation FD Disclosure), Item EX-99.1 (Exhibit EX-99.1). Regulation FD material furnished under Item 7.01, not deemed filed under Exchange Act Section 18.
PHIBRO ANIMAL HEALTH CORP 8-K event analysis
AI summary of each reported item and its exhibits
Item 7.01 · Regulation FD Disclosure
- Regulation FD material furnished under Item 7.01, not deemed filed under Exchange Act Section 18
- Limited liability and incorporation protections for subsequent Securities Act or Exchange Act filings
- No substantive operating, financial, or strategic disclosure in the provided text
Item EX-99.1 · Exhibit EX-99.1
- Brazil’s Ordinance No. 1617 bans antimicrobial growth-promotion additives, including virginiamycin and bacitracin
- 180-day transition period delays commercial impact, with limited fiscal 2026 effect expected
- Post-transition use requires veterinary prescriptions, increasing compliance and channel-management requirements
- Pending therapeutic registrations for virginiamycin could preserve cattle and broiler demand
- PhibroVet digital prescription platform supports regulatory compliance and operational continuity in Brazil
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other PHIBRO ANIMAL HEALTH CORP 8-K filings
Get the next PAHC 8-K as it lands
Follow PAHC for push alerts, or ask the research agent what this filing means.